Skip to main content
OpenTrials
Completed

NCT Number: NCT00265031

HD12 for Advanced Stages

This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hodgkin´s Lymphoma

Age range

16 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hodgkin´s lymphoma (histologically proven)
  • CS(PS) IIB with one or both of the risk factors:
  • bulky mediastinal mass (> 1/3 of maximum transverse thorax diameter)
  • extranodal involvement
  • CS(PS) III, IV
  • written informaed consent

Exclusion criteria

  • Leukocytes <3000/microl
  • Platelets <100000/microl
  • Hodgkin´s Disease as "composite lymphoma"
  • Activity index (WHO) < grade 2

Treatment and study plan

Cyclophosphamide

Drug

Adriamycin

Drug

etoposide

Drug

Procarbazine

Drug

Prednisone

Drug

Vincristine

Drug

Bleomycin

Drug

Radiation Therapy

Procedure

Sponsors and collaborators

Lead sponsor

University of Cologne

Other

Registry information

Important dates

Study start
1999
First posted
Dec 13, 2005
Registry last updated
Jun 25, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.